[go: up one dir, main page]

WO2013009143A3 - Marker for diagnosing diabetic retinopathy - Google Patents

Marker for diagnosing diabetic retinopathy Download PDF

Info

Publication number
WO2013009143A3
WO2013009143A3 PCT/KR2012/005622 KR2012005622W WO2013009143A3 WO 2013009143 A3 WO2013009143 A3 WO 2013009143A3 KR 2012005622 W KR2012005622 W KR 2012005622W WO 2013009143 A3 WO2013009143 A3 WO 2013009143A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetic retinopathy
diagnosing diabetic
marker
diagnosing
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/005622
Other languages
French (fr)
Korean (ko)
Other versions
WO2013009143A2 (en
WO2013009143A9 (en
Inventor
김영수
유형곤
김경곤
김상진
유지영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNU R&DB Foundation filed Critical SNU R&DB Foundation
Publication of WO2013009143A2 publication Critical patent/WO2013009143A2/en
Publication of WO2013009143A9 publication Critical patent/WO2013009143A9/en
Publication of WO2013009143A3 publication Critical patent/WO2013009143A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a composition and a kit comprising an agent for measuring a gene or a protein level that can be used to diagnose and determine the progression of a diabetic retinopathy patient, for diagnosing diabetic retinopathy, a method for providing information for diagnosing diabetic retinopathy, and to a method for diagnosing diabetic retinopathy using the composition and the kit.
PCT/KR2012/005622 2011-07-14 2012-07-13 Marker for diagnosing diabetic retinopathy Ceased WO2013009143A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110070122A KR20130009204A (en) 2011-07-14 2011-07-14 Marker for diagnosing diabetic retinopathy and use thereof
KR10-2011-0070122 2011-07-14

Publications (3)

Publication Number Publication Date
WO2013009143A2 WO2013009143A2 (en) 2013-01-17
WO2013009143A9 WO2013009143A9 (en) 2013-03-28
WO2013009143A3 true WO2013009143A3 (en) 2013-05-30

Family

ID=47506750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/005622 Ceased WO2013009143A2 (en) 2011-07-14 2012-07-13 Marker for diagnosing diabetic retinopathy

Country Status (2)

Country Link
KR (1) KR20130009204A (en)
WO (1) WO2013009143A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020232805B2 (en) * 2019-03-07 2024-03-07 Reti Mark Co., Ltd. Composite marker for diagnosis of diabetic retinopathy and use thereof
WO2020179953A1 (en) * 2019-03-07 2020-09-10 (주)레티마크 Composite marker for diagnosis of diabetic retinopathy and use thereof
WO2020189821A1 (en) * 2019-03-20 2020-09-24 (주)레티마크 Blood marker for diagnosing major blindness-causing eye diseases, and diagnostic method using same
RU2765437C1 (en) * 2021-08-17 2022-01-31 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) Method for determining gene expression level, coding pedf, in oryctolagus cuniculus rabbit eye tissues and a kit for its determining

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEN-BO GAO ET AL., JOURNAL OFPROTEOME RESEARCH., vol. 7, no. 6, 24 April 2008 (2008-04-24), pages 2516 - 2525 *
KIM, GYEONG GON., THESIS FOR DOCTORATE IN SEOUL UNIVERSITY., 2010 *
KYUNGGON KIM ET AL., JOURNAL OFPROTEOME RESEARCH., vol. 9, no. 2, 18 December 2009 (2009-12-18), pages 689 - 699 *

Also Published As

Publication number Publication date
WO2013009143A2 (en) 2013-01-17
KR20130009204A (en) 2013-01-23
WO2013009143A9 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
WO2013009146A3 (en) Marker for diagnosing diabetic retinopathy
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
HK1210831A1 (en) Compositions and methods for detecting protease activity in biological systems
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2014020502A3 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
EA201590027A1 (en) DETECTION METHODS OF DISEASES OR CONDITIONS
WO2012021407A3 (en) Biomarkers for stroke
WO2013163568A3 (en) Methods for evaluating lung cancer status
WO2013153461A3 (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
WO2010136163A8 (en) Secernin-1 as a marker for cancer
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
WO2011156734A3 (en) Method of characterizing vascular diseases
WO2012107841A3 (en) Micro -rna biomarkers for identifying risk of and/or for diagnosing lung tumour and pharmaceutical compositions thereof
WO2010097186A8 (en) Use of s-erbb-3 as a marker for cancer
WO2014043633A8 (en) Use of e-cadherin and vimentin for selection of treatment responsive patients
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
AU2012339149A8 (en) Method for the diagnosis of Niemann-Pick disease
BR112014031957A2 (en) bag3 as biochemical serum and tissue marker
WO2013009143A3 (en) Marker for diagnosing diabetic retinopathy
WO2012049225A3 (en) Marker sequences for systemic lupus erythematosus and the use thereof
WO2015069883A3 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
WO2012081007A3 (en) Methods of diagnosing and treating pancreatic cancer
WO2011003623A3 (en) Method and marker for the individual prognosis and/or the individual detection of neuropathy
WO2014117680A3 (en) Use of trpc6 mrna levels in peripheral blood cells for early detection/diagnosis of senile dementia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12810761

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12810761

Country of ref document: EP

Kind code of ref document: A2